Publication: 4425

Publication: 4425

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).

PubMed

DOI

Google Scholar

Citation:: Ann Oncol

Year:: 2024
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Meta-Analysis
Data Sharing:: Alliance-data-source,-external-user
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:

Parents:: 4074
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:: GSK
Grants:: U10CA180821, U10CA180882, U24CA196171; R01CA229409, UG1CA233184, UG1CA233333, UG1CA233373, P50CA058223, U10CA180868 (NRG Oncology); NSABP Foundation, Inc, .GlaxoSmithKinel

Corr. Author:
Authors:: Aranzazu Fernandez-Martinez Maki Tanioka Sung Gwe Ahn Paola Zagami Tomás Pascual Mattia Rediti Gong Tang Katherine A Hoadley David Venet Naim U Rashid Patricia A Spears Serena Di Cosimo Evandro de Azambuja Anup Choudhury Priya Rastogi Md N Islam Javier Cortes Antonio Llombart-Cussac Sandra M Swain Christos Sotiriou Aleix Prat Charles M Perou Lisa A Carey

Networks:: CAPITAL, LAPS-NC007, PA125

Study: Alliance-A152117
Multiple Studies, or Legacy Studies in Alliance Study:: CALGB-40601, NeoALTTO, NSABP B-41, PAMELA
Phases:: N/A, 2, 3

Keywords: